Pureos Bioventures invests in biotech companies advancing innovative treatments for severe diseases, with a focus on next-generation biological drugs and drug formats. The firm supports high-potential teams with development programs aimed at improving patient outcomes through transformative therapies.
Bevorzugte Reifephase für die erste Finanzierung.
Biotech companies developing innovative therapeutics, particularly next-generation biological drugs, antibody-drug conjugates (ADCs), gene therapies, and precision monoclonal antibodies for severe diseases.
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...